Alerje

Pointe Angels investors beat the unseasonable March heat yesterday to see Innovation presentations, share perspectives, and play Carp Tank?. John-Timothy Anyanwu gave a preview of Carbon Scavenger, a railroad CO2 scrubber that sequesters diesel locomotive exhaust carbon. Cole Confer previewed somaLYNC, a virtual matchmaker for physicians to talk with leading medical Key Opinion Leaders. Scott Craig gave a full Venture Presentation on HiPer Fibers, a U-M spinout producing additives for ultra high-performance concrete. Adam Koehler presented Content Credits, an innovative way for readers to bypass web paywalls while delivering value to publishers and writers. Javier Evelyn gave an update on Alerje's progress, and a major new Investment Partner for its food-allergy intervention technology. Congratulations to our Spirit of Pointe Angels winner Leonard Sachs for his superior Carp Tank? investor-gameplay. Innovation appears undaunted by economic uncertainty. Angels have their pick of promising ventures, at investor-friendly terms. It's good to be an Angel. Adam Kaplan Andrew McColm Aubrey Martinson K. Bobbi Carbone MD MBA Craig Fowler Daniel Sem David C. Bloom David Maas Drew Mcusic G. Edward Kriese Jim Agley Jimmy Gwizdala Ken Olson Kristin Welch Micaela Trexler, PhD Rosario Agley Ryan Ninneman Scott Garberding Sherif El-Tawil Siya Shah Steven Enwright

As we continues to advance our food allergy care platform, we're excited to announce two key additions to our leadership team! These strategic appointments significantly enhance our clinical expertise and regulatory capabilities at a pivotal moment in our company's growth journey. ??

Exciting news from #CTIP portfolio member Alerje! Their epinephrine auto-injector phone case has just earned a patent in Japan, expanding access to fast, reliable emergency medicine. With food allergies on the rise, Alerje continues to innovate for those who need it most. #MedTech #FoodAllergy #Innovation #GlobalHealth

We’re excited to share that Alerje has reached another global milestone! Our epinephrine auto-injector phone case just earned a patent in Japan ????, broadening our reach in delivering fast, reliable emergency medicine. With food allergies affecting more people every day, we remain dedicated to exploring new ways to support those who need it most. ??

Check out the latest updates from our amazing portfolio companies and ecosystem partners! Kudos to Alerje for obtaining its latest U.S. patent in support of their flagship epinephrine device! https://lnkd.in/gzpffdps Check out the latest updates from CareAcademy, including exciting 2024 milestones and a bold vision for 2025!?https://lnkd.in/gcV_7sGW Learn more about Elektra Health's progress in their recently released?2024 Year in Review! https://lnkd.in/e-qqJxhU Dive into BlastPoint’s latest blog and learn more about how Energy burden and engagement impact customer satisfaction. https://lnkd.in/gRgU3GTz Congratulations to it's electric for being named a Top Innovator in Transportation Electrification by Darcy Partners two years in a row! https://lnkd.in/gPtiuD-P Applications for Morgan Stanley’s Inclusive and Sustainable Ventures Lab are officially open! Details and link to apply -> https://lnkd.in/gK9_kbkv Share this post to help us celebrate our founders and follow for more updates!

Innovation doesn’t happen in isolation, it takes a dedicated team of engineers, designers, medical experts and advisors working toward a shared vision. Today, we’re proud to announce that Alerje has secured another key U.S. patent for our flagship epinephrine device, reinforcing our mission to make emergency allergy care more accessible, intuitive, and reliable. With food allergies on the rise, solutions like this are more critical than ever. A huge thank you to the engineers and designers, who over the years continued to push boundaries! ????

One of the most important aspects of being a #foodallergymom is teaching your kids how to advocate for themselves over time. I cover three conversations to have with your teen in one of my latest blogs for WebMD. Please read and share — I hope you find this helpful! #foodallergy #foodallergyawareness #foodallergyadvocate Read it here: https://lnkd.in/eWasP_UP

Luke Barratt (former CEO of Xtract Solutions) recently shared his thoughts on acquiring allergy testing and immunotherapy software from ModMed, emphasizing their extensive experience in entering new markets and enhancing the delivery of care. He expressed excitement about joining forces with ModMed to revolutionize allergy care, aiming to positively impact providers treating allergies. ?? Recent Research Breakthroughs: University of Michigan (July 2024): Researchers have made significant strides in using gel-based inulin immunotherapy to prevent allergic reactions in mice for common food allergies like peanut, egg white, and milk. Clinical trials are on the horizon, bringing hope to millions suffering from food allergies worldwide. The University of British Columbia (February 2024): Researchers have identified sublingual immunotherapy (SLIT) as a safer approach for overcoming food allergies in older children and adolescents, offering a viable alternative to oral immunotherapy. ?? Market Growth: The global allergy immunotherapy market is experiencing significant growth, projected to reach USD 4.50 billion by 2034, with a CAGR of 8.73% between 2025 and 2034. This growth is driven by increasing allergy incidences, growing awareness, and advancements in technology. Download the Exciting Developments in Allergy Immunotherapy Brochure: https://lnkd.in/djyi4Nc9 ?? Key Partnerships: Mitsubishi Gas Chemical (September 2024): A strategic partnership with Alerje, Inc. aims to transform allergy diagnosis and treatment globally, focusing on personalized care solutions. Australia's Groundbreaking Initiative (July 2024): The ADAPT OIT program offers a world-first nationwide oral immunotherapy initiative for babies with peanut allergies, building tolerance for infants under 12 months. Inimmune and Intrommune Therapeutics (January 2024): A collaboration to advance long-acting oral mucosal allergy immunotherapy for peanut allergies, combining Inimmune's desensitization technology with Intrommune's clinical-stage immunotherapy. Top Companies in the Allergy Immunotherapy Market Alerje, Inc. ALK-Abello A/S Allergy Therapeutics Biomay AG DBV Technologies HollisterStier Allergy Inimmune Intrommune Therapeutics, Inc. LETI Pharma Merck Group Siolta Therapeutics Stallergenes Greer Torii Pharmaceutical Co Ltd ?? The allergy immunotherapy field is undoubtedly making incredible strides toward better treatments and outcomes for patients around the world. As market leaders and innovators continue to push boundaries, we can expect even more exciting advancements in the near future. #AllergyCare #Immunotherapy #HealthcareInnovation #FoodAllergyTreatment #MarketGrowth #Partnerships #MedicalResearch #ClinicalTrials #HealthTech

Managing food allergies can feel overwhelming, but as our Clinical Advisor Dr. Lisa Lombard, Ph.D. reminds us: your breath is your constant companion and most powerful tool for managing stress. Whether you're reading labels at the grocery store, dining out, or facing a new situation, take a moment to breathe mindfully. Simple, focused breathing can help you stay grounded and make confident decisions about food safety. It's a practice you can use anywhere, anytime - no special tools required. Just breathe, assess, and proceed with clarity. ?? Share your go-to method for staying calm while navigating food allergies in the comments below. #FromWorriesToWellness #FoodAllergy #MentalHealth

Dr. Carlos Bosques, CEO of the Food Allergy Science Initiative, commented on his appointment as the new CEO that he aims to advance scientific knowledge, find innovative solutions, and provide hope and relief to patients and families affected by food allergies. Such steps are necessary as food allergies impact millions of people worldwide, and the availability of very limited treatment options. Recent Developments in the Food Allergy Treatment Market ? In July 2024, researchers from the University of Michigan identified inulin, a potential new treatment for food allergies. The study published in Nature Materials journal indicated that inulin gel-based oral immunotherapy can stop allergic reactions in mice by targeting bacteria in the gut. ? In July 2024, Stallergenes Greer announced that it received U.S. FDA approval for Palforzia (Peanut Allergen Powder) for the treatment of peanut allergy in toddlers (1-3 years). The new drug is the first and only approved oral immunotherapy for mitigating allergic reactions, including anaphylaxis that may occur with accidental exposure to peanuts. Top Companies in the Food Allergy Treatment Market Alerje, Inc. Camallergy Cour Pharmaceuticals Development Co., Inc. DBV Technologies Genentech HAL Allergy Group Inimmune Intrommune Therapeutics NemaGen Discoveries PROTA THERAPEUTICS PTY LTD Siolta Therapeutics Stallergenes Greer Vedanta Biosciences, Inc. You can place an order or ask any questions, please feel free to contact us at [email protected]